Persistent Depression Associated with Taxane-Based Chemotherapy
cancerpage.com -
NEW YORK AUG 19, 2008 (Reuters Health) - Emotional recovery is delayed in patients with breast cancer who receive taxane-based chemotherapy, Ohio State University researchers report in the August 1 issue of Cancer.
Dr. Lisa M. Thornton and colleagues in Columbus conducted a longitudinal, case-control study assessing quality of life and toxicity in 227 patients with stage II/III breast cancer.
There were 35 patients who received taxane as part of adjuvant chemotherapy, and they were compared with 83 matched patients receiving adjuvant chemotherapy without taxane.
"As expected, patients in the taxane group experienced significantly higher rates of selected toxicities, including arthralgia/myalgia (45% versus 26%) and ataxia (20% versus 5%)," Dr. Thornton's team reports.
User comments (0)
Sorted by: Oldest first